OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press73810.17650/1818-8346-2009-0-2-35-41HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯResults of multiple myeloma treatment with bortezomibРезультаты лечения множественной миеломы препаратом бортезомибPospelovaT. I.ПоспеловаТ. И.
Russian Federation

Novosibirsk

Новосибирск

SkvortzovaN. V.СкворцоваН. В.
Russian Federation

Novosibirsk

Наталия Валерьевна Скворцова

Новосибирск

nata+sk78@mail.ruNechunaevaI. N.НечунаеваИ. Н.
Russian Federation

Novosibirsk

Новосибирск

State Medical UniversityГосударственный медицинский университетHematological CenterГородской гематологический центр270520092354125112022251120222009https://oncohematology.abvpress.ru/ongm/article/view/738

Bortezomib efficacy in I, II and subsequent therapy lines was studied at 51 multiple myeloma (MM) patients in Novosibirsk Hematological Center. The median of age was 66 years (39—87); patients have received from 4 to 12 therapy courses, totally — 363 courses. Total efficacy of the I line therapy was 80%. Complete remission has been achieved in 60% of patients. Efficacy of Bortezomib monotherapy and in combination with glucocorticoids in case of progression and refractory MM was 75,7%. Bortezomib was effective even at repeated administration to patients had receied it or other components of combined regimes earlier (total response — 46,2%). Bortezomib side effects were predicted and managed; most significant of them are gastrointestinal, hematologic, asthenia and peripheral neuropathia. Thus, bortezomib is highly effective drug, important in MM therapy as I and subsequent therapy line and result in significantly increase of overall survival.

Оценивали эффективность применения бортезомиба в терапии 1–2-й и последующих линий у 51 пациента с множественной миеломой (MM), наблюдавшихся в Городском гематологическом центре Новосибирска. Медиана возраста больных составила 66 (39–87) лет, проведено от 4 до 12 курсов терапии, суммарно – 363 курса. Общая эффективность терапии 1-й линии составила 80%. У 60% пациентов достигнута полная ремиссия. При прогрессировании или рефрактерной ММ эффективность бортезомиба в монорежиме и в сочетании с глюкокортикоидами составила 75,7%. Бортезомиб был достаточно эффективен при повторном назначении у пациентов, ранее получавших его и другие компоненты комбинированного режима (общий ответ – 46,2%). Побочные эффекты бортезомиба были предсказуемыми и управляемыми, наиболее значимыми из них являются гастроинтестинальные, гематологические, астения и периферическая нейропатия. Таким образом, бортезомиб – высокоэффективный препарат, играющий важную роль в терапии MM в качестве 1-й и последующих линий и способствующий достоверному увеличению общей выживаемости пациентов.

bortezomibcombined regimesmultiple myelomaproteasome inhibitorбортезомибкомбинированные режимымножественная миеломаингибитор протеасом1. Richardson P., Mitsiades C., Schlossman R. et al. The treatment of relapsed and refractory multiple myeloma. Hematology, American Society of Hematology, Education Program Book, 2007. p. 317—23.Richardson P., Mitsiades C., Schlossman R. et al. The treatment of relapsed and refractory multiple myeloma. Hematology, American Society of Hematology, Education Program Book, 2007. p. 317—23.2. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему. Алматы, 2007.Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома. Современный взгляд на проблему. Алматы, 2007.3. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521—34.Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521—34.4. Montagut C., Rovira A., Mellado B. et al. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Drugs Today 2005;41:299—315.Montagut C., Rovira A., Mellado B. et al. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Drugs Today 2005;41:299—315.5. Karin M., Cao Y., Greten F.R., Li Z.W. Nf-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301—10.Karin M., Cao Y., Greten F.R., Li Z.W. Nf-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301—10.6. Mitsiades N., Mitsiades C.S., Richardson P.G. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377—80.Mitsiades N., Mitsiades C.S., Richardson P.G. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377—80.7. Kumar S.K., Rajkumar S.V., Dispenzieri A. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516—20.Kumar S.K., Rajkumar S.V., Dispenzieri A. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516—20.8. Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609—17.Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609—17.9. Richardson P.G., Sonneveld P., Schuster M.W. et al. Bortezomib or highdose dexametesone for multiple myeloma. N Engl J Med 2005;352:2487—98.Richardson P.G., Sonneveld P., Schuster M.W. et al. Bortezomib or highdose dexametesone for multiple myeloma. N Engl J Med 2005;352:2487—98.10. Kropff M.H., Bisping G., Wenning D. et al. Bortezomib in combination with dexametasone for relapsed multiple myeloma. Leuk Res 2005;29:587—90.Kropff M.H., Bisping G., Wenning D. et al. Bortezomib in combination with dexametasone for relapsed multiple myeloma. Leuk Res 2005;29:587—90.11. Popat R., Oakervee H., Williams C. et al. Bortezomib, low-dose intravenous melphalan and dexametasone for patients with relapsed multiple myeloma. Haematologica 2008;93:Abstr 918.Popat R., Oakervee H., Williams C. et al. Bortezomib, low-dose intravenous melphalan and dexametasone for patients with relapsed multiple myeloma. Haematologica 2008;93:Abstr 918.12. San Miguel J.F., Schlag R., Khuageva N. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906—17.San Miguel J.F., Schlag R., Khuageva N. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906—17.13. Blade J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115—23.Blade J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115—23.14. Ma M.H., Yang H.H., Parker K. et al. The proteasome inhibitor pS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136—44.Ma M.H., Yang H.H., Parker K. et al. The proteasome inhibitor pS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136—44.15. Hideshima T., Richardson P., Chauhan D. et al. The proteasome inhibitor pS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071—6.Hideshima T., Richardson P., Chauhan D. et al. The proteasome inhibitor pS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071—6.16. Mitsiades N., Mitsiades C.S., Richardson P.G. et al. The proteasome inhibitor pS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003;101:2377—80.Mitsiades N., Mitsiades C.S., Richardson P.G. et al. The proteasome inhibitor pS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003;101:2377—80.17. Orlowski R.Z., Voorhees P.M., Garcia R.A. et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients withadvanced hematologic malignancies. Blood 2005;105:3058—65.Orlowski R.Z., Voorhees P.M., Garcia R.A. et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients withadvanced hematologic malignancies. Blood 2005;105:3058—65.18. Berenson J.R., Yang H.H., Sadler K. et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937—44.Berenson J.R., Yang H.H., Sadler K. et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937—44.19. Leoni F., Casini C., Breschi C. et al. Low dose bortezomib, dexamethasone, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma. Haematologica 2006;91:281.Leoni F., Casini C., Breschi C. et al. Low dose bortezomib, dexamethasone, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma. Haematologica 2006;91:281.20. Richardson P.G., Briemberg H., Jagannath S.et al. Characterization and reversibility of peripheral neuropaty in patients with advanced multiple myeloma treated with bortezomib. Summit and Crest study group. Hematol J 2004;5:129.Richardson P.G., Briemberg H., Jagannath S.et al. Characterization and reversibility of peripheral neuropaty in patients with advanced multiple myeloma treated with bortezomib. Summit and Crest study group. Hematol J 2004;5:129.21. Mateos M.V., Hernandez J.M., Hernandez M.T. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93(4):560—5.Mateos M.V., Hernandez J.M., Hernandez M.T. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93(4):560—5.